Evidence map›Paper›PMID 38413734›Full record

ArticleEMBO reports2024

A neuroligin-2-YAP axis regulates progression of pancreatic intraepithelial neoplasia.

Emanuele Middonti, Elena Astanina, Edoardo Vallariello, Roxana Maria Hoza, Jasna Metovic, Rosella Spadi, Carmen Cristiano, Mauro Papotti, Paola Allavena, Francesco Novelli and 7 more

Open access · diamondAbstract read
In one paragraph

Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Emanuele MiddontiDepartment of Oncology, University of Torino, 10043, Orbassano, Italy. Emanuele.middonti@unito.it.ORCID 0000-0002-6961-4823
Elena AstaninaDepartment of Oncology, University of Torino, 10043, Orbassano, Italy.
Edoardo VallarielloDepartment of Oncology, University of Torino, 10043, Orbassano, Italy.ORCID 0000-0001-9156-3957
Roxana Maria HozaDepartment of Oncology, University of Torino, 10043, Orbassano, Italy.
Jasna MetovicDepartment of Oncology, University of Torino, 10043, Orbassano, Italy.
Rosella SpadiSC Oncologia Medica, Città della Salute e della Scienza di Torino, 10126, Torino, Italy.ORCID 0000-0003-2589-2415
Carmen CristianoSC Oncologia Medica, Città della Salute e della Scienza di Torino, 10126, Torino, Italy.
Mauro PapottiDepartment of Oncology, University of Torino, 10043, Orbassano, Italy.
Paola AllavenaIRCCS, Humanitas Clinical and Research Center, 20089, Rozzano, Italy.ORCID 0000-0002-6697-6028
Francesco NovelliDepartment of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.
Sushant ParabDepartment of Oncology, University of Torino, 10043, Orbassano, Italy.
Paola CappelloDepartment of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Torino, Italy.ORCID 0000-0002-5321-7794
Aldo ScarpaApplied Research Center (ARC-NET), University of Verona, 37134, Verona, Italy.
Rita LawlorApplied Research Center (ARC-NET), University of Verona, 37134, Verona, Italy.
Massimo Di MaioDepartment of Oncology, University of Torino, 10043, Orbassano, Italy.
Marco Arese *Department of Oncology, University of Torino, 10043, Orbassano, Italy.
Federico Bussolino *Department of Oncology, University of Torino, 10043, Orbassano, Italy. Federico.Bussolino@unito.it.ORCID 0000-0002-5348-1341
Candiolo Cancer Institute · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITUniversity of Verona · ITA. O. Ordine Mauriziano di Torino · ITHumanitas University · ITUniversity of Turin · IT

Funding

AREM_RILO_19_01 Bando Ricerca Locale 2019Fondazione AIRC per la ricerca sul cancro ETS (AIRC) grants 22910,12182 and 18652Fondazione AIRC per la ricerca sul cancro ETS (AIRC) IG 19931Fondazione CRT (CRT Foundation) no. 2020.0719Fondazione Ricerca Molinette (Fondazione Ricerca Tumori Molinette) Fondo CD38 and Fondo Ursula e Giorgio CytronFPRC 5xmille MIUR ProactiveMinistero dell'Università e della Ricerca (MUR) PRIN 2017,grant 2017237P5X,PRIN 2022 grant 2022HREZJT,PNRR 3F 4 Health
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a dismal prognosis that arises from precursor lesions called pancreatic intraepithelial neoplasias (PanINs). Progression from low- to high-grade PanINs is considered as tumor initiation, and a deeper understanding of this switch is needed. Here, we show that synaptic molecule neuroligin-2 (NLGN2) is expressed by pancreatic exocrine cells and plays a crucial role in the regulation of contact inhibition and epithelial polarity, which characterize the switch from low- to high-grade PanIN. NLGN2 localizes to tight junctions in acinar cells, is diffusely distributed in the cytosol in low-grade PanINs and is lost in high-grade PanINs and in a high percentage of advanced PDACs. Mechanistically, NLGN2 is necessary for the formation of the PALS1/PATJ complex, which in turn induces contact inhibition by reducing YAP function. Our results provide novel insights into NLGN2 functions outside the nervous system and can be used to model PanIN progression.

Indexed as

Carcinoma in SituCarcinoma, Pancreatic DuctalPancreatic NeoplasmsCell Transformation, NeoplasticHumansNeuroliginsNeuroliginsCell PolarityContact InhibitionNeuroliginPancreatic Intraepithelial NeoplasiaYAP

Identifiers

PMID38413734
PMCPMC11014856
OpenAlexW4392200308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.